Zogenix’s seizure drug filing fails to pass U.S. FDA scrutiny
(Reuters) – The U.S. Food and Drug Administration on Monday refused to fully review the marketing application for Zogenix Inc’s treatment for seizures associated with Dravet syndrome, a rare form…